Kringle Pharma (TYO:4884) has formed a US subsidiary, Kringle Pharma USA, to expand its global presence and accelerate the development of its lead program for acute spinal cord injury.
The new subsidiary will be headquartered in Georgia and led by President Matt Vogelhuber, according to its Tokyo bourse filing on Thursday.
Vogelhuber brings over 30 years of industry experience from companies like Eli Lilly and Myriad Genetics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.